Physician

Padmaja Reddy Bojanapally, M.D

According to 2025 Medicare claims, Padmaja Bojanapally, M.D (NPI: 1790949576) practices hematology/oncology in the Scranton--Wilkes-Barre, PA market, with the plurality of this provider's patient population coming from Lackawanna, PA. This provider's primary affiliated billing organization is HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (NPI: 1164538724; TIN: 232137083) and primary practice location at 18512-3169. Bojanapally is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Bojanapally's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 899 traditional Medicare patients, billed 186,662 HCPCS/CPT codes, and received $3,706,671 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,871 prescription claims across 318 beneficiaries totaling $4,711,371 in drug costs, led by Ibrance (Palbociclib). DME data shows 44 claims. Open Payments data shows 21 records totaling $497. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,852,129 to $3,706,671. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,068,665 to $4,711,371. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,539 and ending at $814.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	745	143,281	$1,852,129
2016	683	135,780	$1,750,466
2017	756	180,565	$2,566,599
2018	772	192,045	$2,546,855
2019	858	229,229	$3,049,729
2020	824	262,862	$3,816,399
2021	833	243,508	$3,988,102
2022	967	246,854	$3,734,827
2023	920	195,056	$3,564,249
2024	899	186,662	$3,706,671

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	193	1,010	$1,068,665
2016	194	1,217	$1,233,087
2017	190	1,175	$1,145,318
2018	232	1,189	$1,361,081
2019	277	1,453	$2,479,570
2020	264	1,637	$3,084,512
2021	309	2,003	$3,963,220
2022	324	2,059	$4,906,285
2023	307	1,836	$4,391,882
2024	318	1,871	$4,711,371

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	66	$27,296
2016	N/R	109	$41,672
2017	N/R	50	$8,965
2018	N/R	63	$7,410
2019	N/R	79	$47,679
2020	N/R	102	$70,417
2021	N/R	47	$1,561
2022	N/R	11	$606
2023	N/R	N/R	N/R
2024	N/R	44	$897

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	530	1,441	$87
80053	Blood test, comprehensive group of blood chemicals	726	2,234	$10
83550	Iron binding capacity	343	810	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	739	2,357	$8
83540	Iron level	343	811	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	46	1,281	$687,040
Revlimid	Lenalidomide	37	1,036	$650,805
Imbruvica	Ibrutinib	26	728	$414,552
Verzenio	Abemaciclib	26	728	$379,379
Pomalyst	Pomalidomide	16	434	$361,129

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$439
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	22	$326
J8520	Capecitabine, oral, 150 mg	N	N/R	11	$132

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$497	SOBI, INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Padmaja Reddy Bojanapally, M.D?

Tedicare shows public-source Medicare data for Padmaja Reddy Bojanapally, M.D (NPI 1790949576), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Padmaja Reddy Bojanapally, M.D have ACO affiliation data?

Padmaja Reddy Bojanapally, M.D is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Padmaja Reddy Bojanapally, M.D?

Padmaja Reddy Bojanapally, M.D is linked to HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (billing NPI 1164538724) in the available physician profile data.

Does Padmaja Reddy Bojanapally, M.D have Open Payments data?

Padmaja Reddy Bojanapally, M.D has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.